Provided by Tiger Trade Technology Pte. Ltd.

Regeneron Pharmaceuticals

805.02
-14.0700-1.72%
Post-market: 804.00-1.0200-0.13%19:30 EDT
Volume:527.74K
Turnover:425.48M
Market Cap:82.88B
PE:19.91
High:819.09
Open:819.09
Low:801.22
Close:819.09
52wk High:859.34
52wk Low:575.93
Shares:102.95M
Float Shares:98.88M
Volume Ratio:0.82
T/O Rate:0.53%
Dividend:3.64
Dividend Rate:0.45%
EPS(TTM):40.43
EPS(LYR):41.48
ROE:14.04%
ROA:6.53%
PB:2.61
PE(LYR):19.41

Loading ...

A 42% Risk Reduction—and an 18% Stock Drop

Bellwether Stocks Movement
·
Yesterday

Earning Preview: Regeneron Pharmaceuticals this quarter’s revenue is expected to increase by 26.61%, and institutional views are predominantly bullish

Earnings Agent
·
Oct 23

What Regeneron Pharmaceuticals Buyers Were Betting On

Simply Wall St.
·
4 hours ago

Regeneron Pharmaceuticals - Libtayo Achieves 37% Reduction in Risk of Death at 44 Months (Hr: 0.63)

THOMSON REUTERS
·
4 hours ago

Regeneron Pharmaceuticals - Libtayo Confirms Sustained Disease-Free Survival Benefit Including Mrd Negative Patients

THOMSON REUTERS
·
4 hours ago

Regeneron's Libtayo Cuts Death Risk 37% in High-Risk Skin Cancer Trial Follow-up

Reuters
·
4 hours ago

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

GlobeNewswire
·
4 hours ago

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Yesterday

Regeneron Pharmaceuticals (REGN) Pushes Ahead In Weight Loss With Two Distinct Drug Bets

Simply Wall St.
·
Oct 23

Regeneron Pharmaceuticals Inc. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Oct 23

Evercore ISI Adjusts Price Target on Regeneron Pharmaceuticals to $900 From $850

MT Newswires Live
·
Oct 22

TD Cowen Adjusts Price Target on Regeneron Pharmaceuticals to $980 From $960

MT Newswires Live
·
Oct 21

Regeneron Pharmaceuticals, Inc. : TD Cowen Raises Target Price to $980 from $960

THOMSON REUTERS
·
Oct 21

Regeneron Pharmaceuticals Inc. Stock Underperforms Tuesday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Oct 21

Movement Alert|Regeneron Pharmaceuticals Intraday Rise 3.06% in Regular Trading, Libtayo Dosing Update Wins Positive EU Regulatory Recommendation

Market Focus
·
Oct 20

AstraZeneca-Amgen Asthma Drug Hits 69% Remission in Esophageal Disease Trial

Reuters
·
Oct 20

One Failed Endpoint Just Erased Most of EyePoint’s Value

Bellwether Stocks Movement
·
Oct 20

Regeneron Pharmaceuticals Inc. Stock Outperforms Competitors Despite Losses on the Day

Dow Jones
·
Oct 20

Regeneron Pharma is Maintained at Overweight by Piper Sandler

Dow Jones
·
Oct 20

EyePoint to Cut Workforce by Half After Experimental Drug Fails Second Late-Stage Trial

Reuters
·
Oct 19